- Title
- Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update
- Creator
- David Stead
- Description
- What is new in the 2020 guidelines update? Key updates ÿ A recommendation for dolutegravir (DTG)-based therapies as the preferred first-line antiretroviral therapy (ART) option (section 11). ÿ Updated guidelines for second- and third-line ART regimens (section 13). ÿ New recommendations on the management of patients on DTG-based therapies who have an elevated viral load (section 12). ÿ A lowering of the threshold for virological failure from 1000 copies/mL to 50 copies/mL (section 8). ÿ A recommendation against routine cluster of differentiation 4 (CD4+) monitoring in patients who are clinically well once the CD4+ count is > 200 cells/μL (section 9). ÿ Updated recommendations for isoniazid preventive therapy (IPT) in human immunodeficiency virus (HIV)-positive patients (section 27). ÿ A recommendation for the use of low-dose prednisone as prophylaxis for paradoxical tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS) in TB/HIV co-infected patients commencing ART within 1 month of TB therapy (section 26).
- Date
- 2020
- Type
- text, article
- Identifier
- http://hdl.handle.net/11260/3281
- Identifier
- vital:43293
- Identifier
- https://doi.org/10.4102/sajhivmed.v21i1.1115
- Format
- 1-39 pages, pdf
- Publisher
- AOSIS
- Language
- English
- Relation
- Southern African Journal of HIV Medicine, Nel J, Dlamini S, Meintjes G, et al. Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. S Afr J HIV Med. 2020;21(1), a1115. https://doi.org/10.4102/sajhivmed.v21i1.1115, Southern African Journal of HIV Medicine volume 21 Issue 1 16 09 2020 (Online) 2078-6751, (Print) 1608-9693
- Rights
- © 2020 AJHTL /Author/s, © 2020. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License
- Hits: 366
- Visitors: 365
- Downloads: 35
Thumbnail | File | Description | Size | Format | |||
---|---|---|---|---|---|---|---|
View Details | SOURCE1 | 1115-8930-2-PB.pdf | 1 MB | Adobe Acrobat PDF | View Details |